Masking T cell engagers mitigates on-target off-tumor activity

Aliyah B Silver^{1

2}, Jeremy Wang^{2

3}, Jamie B Spangler^{4

5

6

7

8

9

10}

Affiliations

¹ Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
² Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
⁴ Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jamie.spangler@jhu.edu.
⁵ Department of Chemical and Biomedical Engineering, Johns Hopkins University Whiting School of Engineering, Baltimore, MD, USA. jamie.spangler@jhu.edu.
⁶ Institute for NanoBioTechnology, Johns Hopkins University Whiting School of Engineering, Baltimore, MD, USA. jamie.spangler@jhu.edu.
⁷ Department of Materials Science and Engineering, Johns Hopkins University Whiting School of Engineering, Baltimore, MD, USA. jamie.spangler@jhu.edu.
⁸ Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jamie.spangler@jhu.edu.
⁹ Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jamie.spangler@jhu.edu.
¹⁰ Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jamie.spangler@jhu.edu.

Comment

Aliyah B Silver et al. Nat Cancer. 2023 Apr.

. 2023 Apr;4(4):439-441.

doi: 10.1038/s43018-023-00529-8.

Aliyah B Silver^{1

2}, Jeremy Wang^{2

3}, Jamie B Spangler^{4

5

6

7

8

9

10}

¹ Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
² Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
⁴ Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jamie.spangler@jhu.edu.
⁵ Department of Chemical and Biomedical Engineering, Johns Hopkins University Whiting School of Engineering, Baltimore, MD, USA. jamie.spangler@jhu.edu.
⁶ Institute for NanoBioTechnology, Johns Hopkins University Whiting School of Engineering, Baltimore, MD, USA. jamie.spangler@jhu.edu.
⁷ Department of Materials Science and Engineering, Johns Hopkins University Whiting School of Engineering, Baltimore, MD, USA. jamie.spangler@jhu.edu.
⁸ Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jamie.spangler@jhu.edu.
⁹ Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jamie.spangler@jhu.edu.
¹⁰ Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jamie.spangler@jhu.edu.

No abstract available

Comment on

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors.
Cattaruzza F, Nazeer A, To M, Hammond M, Koski C, Liu LY, Pete Yeung V, Rennerfeldt DA, Henkensiefken A, Fox M, Lam S, Morrissey KM, Lange Z, Podust VN, Derynck MK, Irving BA, Schellenberger V. Cattaruzza F, et al. Nat Cancer. 2023 Apr;4(4):485-501. doi: 10.1038/s43018-023-00536-9. Epub 2023 Mar 30. Nat Cancer. 2023. PMID: 36997747 Free PMC article.

1. Arvedson, T. et al. Annu. Rev. Cancer Biol. 6, 17–34 (2022). - DOI
1. Goebeler, M.-E. & Bargou, R. C. Nat. Rev. Clin. Oncol. 17, 418–434 (2020). - DOI - PubMed
1. Vafa, O. & Trinklein, N. D. Front. Oncol. 10, 446 (2020). - DOI - PubMed - PMC
1. Baeuerle, P. A. & Wesche, H. Curr. Opin. Oncol. 34, 552–558 (2022). - DOI - PubMed - PMC
1. Cattaruzza, F. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00536-9 (2023).